Why the study?
Does troglitazone inhibit the voltage-dependent L-type Ca2+ current in single cardiac ventricular myocytes of guinea pigs?
Does troglitazone inhibit the voltage-dependent L-type Ca2+ current in single cardiac ventricular myocytes of guinea pigs?
Troglitazone inhibits L-type Ca2+ channels in guinea pig ventricular myocytes at therapeutic concentrations, suggesting potential cardioprotective effects in diabetic conditions.
Answers are grounded in this paper and cite their sources.
Troglitazone may inhibit cardiac L-type Ca2+ currents at therapeutic levels in animal models; leaves open human translation for diabetic cardioprotection.
We investigated the effects of troglitazone, a new orally active hypoglycemic agent, on the voltage-dependent L-type Ca2+ current in single cardiac ventricular myocytes of guinea pigs by the whole-cell voltage clamp technique. Troglitazone blocked the Ca2+ currents in a concentration-dependent manner. The inhibitory effect was more potent at the holding potential (HP) of - 50 mV than at - 80 mV. The half-maximum inhibiting concentration (IC50) of troglitazone was 0.8 microM with the Hill coefficient of 0.84 at -50 mV HP. In contrast, the IC50 value was higher than 10 microM at -80 mV HP. These results suggest that troglitazone at therapeutic concentrations inhibit the Ca2+ channels and may exert cardioprotective effects in diabetic conditions.
No takes yet. Share an insight, caveat, or question.
Katoh et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: